Company Encyclopedia
View More
name
Salubris
002294.SZ
Shenzhen Salubris Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of medicines and medical devices in China. The company offers drugs for various therapeutic fields, such as thrombosis, hypertension and related diseases, osteoporosis, and infections, as well as anti-osteolysis, antiallergic, antiepileptic, and antidepressant medicines. It also develops Sacubitril Allisartan Calcium, Allisartan Isoproxil Amlodipine Besylate Tablets, and Allisartan IsoproxilIndapamide Sustained-release Tablets, which are in phase III clinical trial for treatment of hypertension; Enarodustat, a drug for renal anemia; SAL056, SAL001, SAL023 medicine used for treating osteoporosis; and Fotagliptin, and SAL015 for diabetes which are under phase III clinical trial.
3.157 T
002294.SZMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
PharmaceuticalsIndustry
Industry Ranking5/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE7.74%B
    • Profit Margin15.82%A
    • Gross Margin74.85%A
  • Growth ScoreB
    • Revenue YoY8.76%B
    • Net Profit YoY10.15%C
    • Total Assets YoY7.34%B
    • Net Assets YoY3.32%C
  • Cash ScoreB
    • Cash Flow Margin632.28%C
    • OCF YoY8.76%B
  • Operating ScoreC
    • Turnover0.4C
  • Debt ScoreA
    • Gearing Ratio18.69%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Shenzhen Salubris Pharmaceuticals Gets China Approval for Chronic Kidney Disease Tablet Clinical Trials

    Shenzhen Salubris Pharmaceuticals Gets China Approval for Chronic Kidney Disease Tablet Clinical Trials

    marketscreener·
    SZ
    002294
    -2.12%
    marketscreener·
    SZ
    002294
    -2.12%

    Salubris Pharmaceuticals Q3 Profit Up 31%, Revenue Rises 16%

    Salubris Pharmaceuticals Q3 Profit Up 31%, Revenue Rises 16%

    marketscreener·
    SZ
    002294
    -2.12%
    marketscreener·
    SZ
    002294
    -2.12%

    Salubris: Net profit of RMB 215.6 million in the third quarter

    Zhitong·
    SZ
    002294
    -2.12%
    Zhitong·
    SZ
    002294
    -2.12%

    Shenzhen Salubris Pharmaceuticals Gets Acceptance of Clinical Trial Application for Elevated Lipoprotein Drug

    Shenzhen Salubris Pharmaceuticals Gets Acceptance of Clinical Trial Application for Elevated Lipoprotein Drug

    marketscreener·
    SZ
    002294
    -2.12%
    marketscreener·
    SZ
    002294
    -2.12%

    Salubris SAL0137 drug clinical trial application accepted

    According to the Zhitong Finance APP, Salubris announced that the company has received the acceptance notice issued by the National Medical Products Administration. The clinical trial application for the innovative small molecule drug SAL0137 (project code: SAL0137) developed by the company has been accepted. SAL0137 is an oral small molecule drug developed by the company with independent intellectual property rights. The application submitted by the company is for the clinical trial of SAL0137 for the treatment of elevated lipoprotein (a)

    Zhitong·
    SZ
    002294
    -2.12%
    Zhitong·
    SZ
    002294
    -2.12%
    © 2025 Longbridge｜Disclaimer